KD Logo

President and CEO, Sandrock Alfred sold 12,115 shares of Voyager Therapeutics Inc [VYGR]

Voyager Therapeutics Inc’s recently made public that its President and CEO Sandrock Alfred unloaded Company’s shares for reported $0.12 million on Apr 02 ’24. In the deal valued at $9.86 per share,12,115 shares were sold. As a result of this transaction, Sandrock Alfred now holds 322,839 shares worth roughly $2.74 million.

Then, Swartz Robin sold 1,357 shares, generating $13,407 in total proceeds. Upon selling the shares at $9.88, the Chief Operating Officer now owns 117,004 shares.

Before that, Sandrock Alfred sold 13,033 shares. Voyager Therapeutics Inc shares valued at $97,226 were divested by the President and CEO at a price of $7.46 per share. As a result of the transaction, Sandrock Alfred now holds 334,954 shares, worth roughly $2.84 million.

Guggenheim initiated its Voyager Therapeutics Inc [VYGR] rating to a Buy in a research note published on March 26, 2024; the price target was $22. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in mid March with a ‘”a Buy”‘ rating. Citigroup began covering VYGR with “Buy” recommendation on March 07, 2024. Wells Fargo revised its rating on January 02, 2024. It rated VYGR as “an Overweight” which previously was an “an Equal weight”.

Price Performance Review of VYGR

On Tuesday, Voyager Therapeutics Inc [NASDAQ:VYGR] saw its stock unchanged to $8.48. Over the last five days, the stock has lost -3.31%. Voyager Therapeutics Inc shares have risen nearly 0.47% since the year began. Nevertheless, the stocks have fallen -18.77% over the past one year. While a 52-week high of $14.34 was reached on 01/02/24, a 52-week low of $6.06 was recorded on 01/17/24. SMA at 50 days reached $8.79, while 200 days put it at $8.17. A total of 0.57 million shares were traded, compared to the trading of 0.39 million shares in the previous session.

Levels Of Support And Resistance For VYGR Stock

The 24-hour chart illustrates a support level at 8.21, which if violated will result in even more drops to 7.93. On the upside, there is a resistance level at 8.81. A further resistance level may holdings at 9.13. The Relative Strength Index (RSI) on the 14-day chart is 51.11, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.15, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 33.70%. Stochastics %K at 65.58% indicates the stock is a holding.

The most recent change occurred on May 10, 2023 when Truist began covering the stock and recommended ‘”a Buy”‘ rating along with a $18 price target.

Most Popular

[the_ad id="945"]